All Videos

Whitney Tolpinrud, MD, discusses how personalized skin care can evolve from acne treatment toward prevention and skin longevity.

Behind each diagnosis is a patient whose work, recreation, and sense of normalcy have been quietly constrained. Personal accounts from both clinicians show why quality-of-life questions belong in every urticaria visit.

Strict photoprotection remains the foundation of EPP care, and only one therapy is approved worldwide. Earlier diagnosis and oral agents that lower protoporphyrin production emerge as the field's most pressing needs.

Years can pass between the first symptoms and a correct EPP diagnosis, and those years carry risk. The discussion links delayed recognition to protoporphyric hepatopathy, iron deficiency, and vitamin D deficiency.

Chronic inducible urticaria is more common than its limited recognition suggests, spans many distinct subtypes, and carries a substantial psychological toll. Accurate diagnosis depends on history and, ideally, standardized provocation testing.

Shannon Trotter, DO, discusses augmented intelligence in skin cancer detection, the approval of remibrutinib for symptomatic dermatographism, and her patient education podcast.

Whitney Tolpinrud, MD, discusses the evolution of personalized prescription skin care, patient expectations in the digital age, and clinical trends.

Tenesha Wallace Hood, MA, of the National Eczema Association (NEA), reviews how state-level data from the NEA's State of AD 2026 National Indicator Report can inform access to atopic dermatitis care.

Distinct pharmacokinetic profiles, including volume of distribution, half-life, and time to steady state, differentiate the two approved hedgehog inhibitors and can be translated into patient-facing counseling during shared decision-making.

Multimodal planning for advanced basal cell carcinoma extends beyond labeled indications, with neoadjuvant hedgehog inhibition, adjuvant radiation, and immune checkpoint inhibitors each occupying a defined place in treatment sequencing.

Andrew Blauvelt, MD, MBA, discusses how to interpret head-to-head, indirect, and long-term efficacy data for emerging oral psoriasis therapies.

Setting realistic timelines and reading quality of life matter as much as counting lesions. The panel also flags a common pitfall: mistaking healing pigment changes for active disease.

Black box warnings, screening requirements, and real-world experience all shape which biologic fits a given patient. The panel applies these safety considerations directly to the first case.

Tenesha Wallace Hood, MA, of the National Eczema Association (NEA), discusses diagnosed prevalence of AD and care access findings from the NEA's State of AD 2026 report.

Speed of onset and long-term durability are often treated as competing priorities. Dr. Armstrong argues they are not mutually exclusive, and details how cardiometabolic comorbidities and how emerging incretin-therapy data may extend treatment options beyond skin clearance alone.

With more biologic classes available than ever, selecting a first-line agent for a treatment-naive patient increasingly depends on comorbidity screening, lifestyle fit, and realistic expectations rather than efficacy data alone.

Adam Friedman, MD, discusses PsA screening, comorbidities, early systemic intervention, and individualized oral therapy selection in psoriasis.

Emma Guttman-Yassky, MD, PhD, explains how biomarkers could match patients with inflammatory skin diseases to the right therapy.

James Song, MD, discusses treatment durability, early intervention, and interpreting long-term clinical trial data in psoriasis.

Phase 2b REZOLVE-AA data presented at EADV 2026 showed sustained and deepening hair regrowth following treatment cessation.

Michael Payette, MD, discusses systemic psoriasis treatment, patient selection, special-site disease, and shared decision-making.

Phase 2b SPOTLIGHT-204 results presented at EADV 2026 showed complete clinical and pathological responses in more than half of patients with high-risk head and neck basal cell carcinoma.

New phase 2 data presented at EADV 2026 demonstrated significant improvements in disease activity with daxdilimab, with responses emerging as early as week 4.

Cynthia Trickett, MPAS, PA-C, and Leigh Ann Pansch, MSN, FNP-BC, DCNP, discussed recognizing hidradenitis suppurativa early, screening for comorbidities, and assessing disease burden.

On this episode of Don't Be Rash, Andrew Krakowski, MD, spoke with Sheilagh Maguiness, MD, about the FDA's approval of bemotrizinol and what the new sunscreen filter means for pediatric patients.

Although hedgehog pathway inhibitors are considered first-line systemic therapy for locally advanced disease, surgical fatigue and patient preference may warrant earlier discussion of oral treatment than current practice patterns reflect.

Without a formal staging system, advanced basal cell carcinoma is defined by the interplay of tumor size, anatomic site, depth, histology, and host factors that may not be apparent on initial biopsy.

EPP arises from reduced ferrochelatase activity and excess protoporphyrin made largely in the bone marrow. Accurate diagnosis depends on choosing the right specimen and the right laboratory, a step commercial assays often get wrong.

Adalimumab, secukinumab, and bimekizumab each carry distinct trial populations and response rates. The panel reviews years of efficacy and safety data behind today's approved HS biologics.

A 29-year-old with years of axillary and groin disease illustrates how psychosocial toll, not just visible lesions, should guide the decision to escalate beyond conventional HS therapy.